| 1.28 -0.03 (-2.29%) | 08-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.79 | 1-year : | 2.1 |
| Resists | First : | 1.53 | Second : | 1.79 |
| Pivot price | 1.31  |
|||
| Supports | First : | 1.19 | Second : | 0.98 |
| MAs | MA(5) : | 1.34 |
MA(20) : | 1.25 |
| MA(100) : | 1.1 |
MA(250) : | 1.21 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.2 |
D(3) : | 57.8 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 1.86 | Low : | 0.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MXCT ] has closed above bottom band by 38.0%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.32 - 1.33 | 1.33 - 1.34 |
| Low: | 1.26 - 1.27 | 1.27 - 1.28 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Wed, 19 Aug 2026
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - vinanet.vn
Wed, 19 Aug 2026
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
Wed, 12 Aug 2026
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Mon, 10 Aug 2026
RIVER GLOBAL INVESTORS LLP Trims MaxCyte Inc (MXCT) Stake -- Sha - GuruFocus
Fri, 07 Aug 2026
MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis - Kalkine
Tue, 04 Aug 2026
MaxCyte, Inc. (MXCT) holder River Global shifts 4.3% voting stake - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 62 (%) |
| Shares Short | 1,240 (K) |
| Shares Short P.Month | 1,520 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | -114.8 % |
| Operating Margin | -140.8 % |
| Return on Assets (ttm) | -10.7 % |
| Return on Equity (ttm) | -20.4 % |
| Qtrly Rev. Growth | -14.5 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -3.77 |
| PEG Ratio | 0 |
| Price to Book value | 0.85 |
| Price to Sales | 4.25 |
| Price to Cash Flow | -5.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|